Biossil key facts
- Developer of an artificial intelligence drug discovery platform designed to offer targeted therapies for biologically defined patient sub-populations.
- It has raised $12.4M; the latest was Seed Round ($8.7M) in Apr 2026.
- Notable investors include Quiet Capital, Panache Ventures, Golden Ventures, Peter Thiel, OpenAI — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Biossil: the Monday email on marks, rounds and moves
Biossil funding rounds
No funding rounds for Biossil are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Biossil investors
6 investors are on record for Biossil, including Quiet Capital, Panache Ventures, Golden Ventures and Peter Thiel.
About Biossil
Developer of an artificial intelligence drug discovery platform designed to offer targeted therapies for biologically defined patient sub-populations. The company's platform offers Excavate, which combines a data-point multi-omics pipeline with population-scale electronic medical record data to translate disease sub-phenotypes into molecular endotypes defined by interactome-scale disease modules, enabling medical researchers to cut drug repurposing time and bring shelved therapies to trial faster.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2023
- Employees
- 4
- Website
- biossil.co/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Biossil doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.